Download Full Text (3.5 MB)
Identify the incidence and severity of drug-drug interactions between commonly prescribed medications and cannabinoids • Medications that are substrates for CYP2C19, CYP2C9 and CYP1A2 are at the greatest risk of interaction with concomitant use of phytocannabinoids or synthetic cannabinoids • Caution is recommended with medications metabolized via UGT or CES1, however information is currently limited and further research is necessary • Lack of universal standards for laboratory testing of cannabinoid products call into question the legitimacy of reported results in currently reported research as the contents of many cannabinoid products are inaccurately labeled
Physician Assistant Studies
Date of Work
drug-drug interactions, cannabinoids, phytocannabinoids, synthetic cannabinoids, hemp, THC, CBD
Medicine and Health Sciences
McRae, Jennifer, "An Analysis of the Incidence and Severity of Drug-Drug Interactions Between Prescribed Pharmaceuticals and Cannabinoids" (2020). Physician Assistant Scholarly Project Posters. 206.